Chronic hepatitis B affects over 250 million people worldwide and can progress to cirrhosis and liver cancer.
Fatty liver is one of the most frequent diseases and affects 25-30% of the world population.
Chronic hepatitis B virus infection is a global health problem.
New trials published with hepatitis B patients suggests the use of liposome nanoparticles with virus antigens for their treatment.